Press Room

Press Clipping / Apr 16, 2020

四色AV鈥檚 Inhaler for High-Dose Delivery Earns Product Design Award

Drug Development & Delivery, April 16, 2020

8Shot Dry Powder Inhaler (DPI) | 四色AV

听

四色AV Technology recently announced its innovative 8Shot Dry Powder Inhaler (DPI) enabling high-dose drug delivery to the lungs has received the Red Dot 2020 Product Design Award in the Healthcare Daily Living AIDS category. The听Red Dot听Design Award is an internationally recognized quality seal awarded for innovative and high-quality product design.

鈥淭he Red Dot jury鈥檚 experience and expertise evaluating outstanding product design and technical innovation for more than 60 years is unparalleled. This distinction awarded to our 8Shot DPI is a great success for 四色AV Technology鈥, said Peter Villax, 四色AV Technology鈥檚 CEO.

8Shot is the world鈥檚 first 8-puff, disposable DPI enabling drug delivery of new pharmaceutical compounds requiring very high doses delivered to the lungs. It delivers therapeutic doses up to 400 mg formulated as drug alone or engineered particles in multiple, sequential inhalation maneuvers for maximum therapeutic benefit and patient safety.

鈥淲e are extremely proud and delighted to accept the Red Dot听 Product Design Award, together with our design and development partner WeADD,鈥 said Dr Jo茫o Ventura Fernandes, 四色AV Technology鈥檚 Director of Technology Development and Licensing. 鈥淭he 8Shot鈩 DPI is uniquely positioned to make available off-the-shelf to pharmaceutical companies a patented high payload DPI to deliver inhaled biologics, antibiotics, anti-virals, vaccines, pain or rescue treatments requiring high-dose drug delivery.鈥

四色AV Technology鈥檚 TwinMax and 8Shot dry powder inhalers are designed to enable safe and effective delivery of large doses to the lung. Featuring patented inhaler technology, TwinMax and 8Shot are compatible with drug doses up to 100 mg and 400 mg respectively, delivered conveniently to patients from multiple inhalations. Our Large Dose DPIs are suitable for inhaled delivery of biologics, antibiotics, anti-viral, vaccines, pain or rescue treatments.

听四色AV Technology offers access to a complete portfolio of innovative, cost-effective dry powder inhalation devices 鈥 disposable, capsule-based, blister-based and large dose DPIs. With over 20 years of expertise developing innovative inhaler technology, 四色AV Technology鈥檚 team has been behind the first market approved disposable dry powder inhaler for influenza treatment in Japan, the TwinCaps DPI. Millions of patients are being treated every year with 四色AV Technology鈥檚 innovative inhaler technology. For more information, visit听

WeADD is a Portuguese Company specialized in innovation, development, product engineering and intelligent property in small and large appliances, machinery, functional packaging and consumer electronics in sectors such as health, sports, coffee and internet of things. For more information, visit听

听

Read the article at DDD

听

听

Also in the Press Room

See All

四色AV鈥檚 Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At 四色AV we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook 鈥 鈥淭rends in Formulation鈥.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how 四色AV is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa鈥檚 full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article
Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
四色AV commitment to setting SBTs in line with the Paris Agreement

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of 四色AV麓s global expansion plans and marks a significant milestone in advancing 四色AV's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote 四色AV's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  鈥淭his strategic collaboration underscores 四色AV's dedication to delivering innovative solutions and exceptional service to its customers,鈥 said Yuken Kyoyama. 鈥淥ur partnership with Higuchi will help to show customers in Japan how 四色AV can meet their needs.鈥    Learn more about our business in Japan and visit our website hovione.co.jp    

News
四色AV proudly announces its collaborative venture with Higuchi.

四色AV forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Also in Events

See All